Vertex: A Reason To Worry: Are Vertex Pharmaceuticals bulls getting too excited about telaprevir?
But others, including Schering-Plough and Vertex Pharmaceuticals, prevailed and now have protease inhibitors in early human trials.
But many on Wall Street have been giving the inside track to a rival drug, Incivek from Vertex Pharmaceuticals.
FORBES: Merck Wins Victory Over Skeptics With Hepatitis C Approval
The result is a big win for developer Vertex Pharmaceuticals and its partner, the Cystic Fibrosis Foundation, a patient group.
The leader in the pack with protease inhibitors for the hepatitis virus, say Markowitz and Jenner, is Vertex Pharmaceuticals of Cambridge, Mass.
Vertex Pharmaceuticals still is leading in the race to develop the first of a new generation of drugs for the deadly liver disease hepatitis C.
In late May Vertex Pharmaceuticals of Boston released results from a giant trial showing its experimental hepatitis C drug, telapravir, cured 75% of patients, far better than existing treatments.
As Vertex Pharmaceuticals and Merck duel to introduce new drugs, ISI analyst Mark Schoenebaum has written that Bristol is among the companies that is closest to developing newer, more tolerable regimens.
The leader in the pack with protease inhibitors for the hepatitis virus, say Markowitz and Jenner, is Vertex Pharmaceuticals (nasdaq: VRTX - news - people ) of Cambridge, Mass.
"There is a big wave of disease coming, and we are just at the start of it, " says Joshua Boger, chief executive of Vertex Pharmaceuticals, which is testing two hepatitis C drugs.
Over the past several days, there has been a great deal of confusion about the extent to which physicians are embracing the new Incivek hepatitis C drug that is sold by Vertex Pharmaceuticals.
FORBES: The Hepatitis C Wars: What Docs Say About The Newest Meds
With a study released this morning, Vertex Pharmaceuticals cemented a key advantage in what is expected to be a booming new market for hepatitis C drugs this morning, increasing its edge over Merck, its main competitor.
In a development that greatly bolsters its standing in the cystic fibrosis market, Vertex Pharmaceuticals late yesterday released data showing a combination of its existing Kalydeco treatment and an experimental medication called VX-661 greatly improved patient breathing.
FORBES: Vertex Scores A Big Win With Its Cystic Fibrosis Experiment
Among the largest underlying components of FBT, in trading today Intermune Incorporated ( NASD: ITMN) is down about 1.5%, Illumina Incorporated ( NASD: ILMN) is off about 1.1%, and Vertex Pharmaceuticals Incorporated ( NASD: VRTX) is lower by about 0.2%.
In the heated race to develop new hepatitis C drugs that boost the cure rate, Wall Street thinks Vertex Pharmaceuticals has a slightly better drug than a rival entry from Merck, and thus will garner the large majority of sales.
FORBES: Why Aren't There AIDS-Style Cocktails for Hepatitis C?
If you want to know why drug research remains a slow and frustrating business even in this golden age of molecular biology, look at the troubles Vertex Pharmaceuticals has gone through to devise a new drug to combat hepatitis C.
Among the largest underlying components of MDY, in trading today Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is up about 0.6%, Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is up about 0.2%, and Equinix Inc ( NASD: EQIX) is lower by about 0.9%.
Among the largest underlying components of IJH, in trading today Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is off about 1.2%, Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is up about 0.5%, and Equinix Inc ( NASD: EQIX) is lower by about 1.6%.
Among the largest underlying components of IJH, in trading today Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is down about 3.9%, Equinix Inc ( NASD: EQIX) is up about 5.9%, and Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is lower by about 0.8%.
Among the largest underlying components of MDY, in trading today Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is up about 3%, Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is up about 1.1%, and Equinix Inc ( NASD: EQIX) is up by about 2%.
Among the largest underlying components of MDY, in trading today Kansas City Southern ( NYSE: KSU) is down about 0.3%, AMETEK, Inc. ( NYSE: AME) is up about 0.6%, and Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is lower by about 1.4%.
Among the largest underlying components of IJH, in trading today Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is down about 0.9%, Equinix Inc ( NASD: EQIX) is off about 0.6%, and Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is higher by about 0.7%.
Among the largest underlying components of IJH, in trading today Vertex Pharmaceuticals, Inc. ( NASD: VRTX) is down about 0.4%, Kansas City Southern ( NYSE: KSU) is off about 0.2%, and AMETEK, Inc. ( NYSE: AME) is lower by about 0.2%.
Among the largest underlying components of FBT, in trading today Biogen Idec Incorporated ( NASD: BIIB) is up about 6.8%, Myriad Genetics Incorporated ( NASD: MYGN) is up about 3.9%, and Vertex Pharmaceuticals Incorporated ( NASD: VRTX) is higher by about 1.8%.
Among the largest underlying components of MDY, in trading today Green Mountain Coffee Roasters ( NASD: GMCR) is off about 2%, Vertex Pharmaceuticals Incorporated ( NASD: VRTX) is off about 1%, and Dollar Tree Incorporated ( NASD: DLTR) is higher by about 0.8%.
FORBES: MidCaps Continue To Bleed Assets As Investors Look Elsewhere
If you want to know why drug research remains a slow and frustrating business even in this golden age of molecular biology, look at the troubles Vertex Pharmaceuticals (nasdaq: VRTX - news - people ) has gone through to devise a new drug to combat hepatitis C.
应用推荐